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Abstract
In head and neck squamous cell carcinoma (HNSCC), mutations of p53 usually coexist with aberrant activation of NF-kappaB
(NF-kB), other transcription factors and microRNAs, which promote tumor pathogenesis. However, how these factors and
microRNAs interact to globally modulate gene expression and mediate oncogenesis is not fully understood. We devised a
novel bioinformatics method to uncover interactive relationships between transcription factors or microRNAs and genes.
This approach is based on matrix decomposition modeling under the joint constraints of sparseness and regulator-target
connectivity, and able to integrate gene expression profiling and binding data of regulators. We employed this method to
infer the gene regulatory networks in HNSCC. We found that the majority of the predicted p53 targets overlapped with
those for NF-kB, suggesting that the two transcription factors exert a concerted modulation on regulatory programs in
tumor cells. We further investigated the interrelationships of p53 and NF-kB with five additional transcription factors, AP1,
CEBPB, EGR1, SP1 and STAT3, and microRNAs mir21 and mir34ac. The resulting gene networks indicate that interactions
among NF-kB, p53, and the two miRNAs likely regulate progression of HNSCC. We experimentally validated our findings by
determining expression of the predicted NF-kB and p53 target genes by siRNA knock down, and by examining p53 binding
activity on promoters of predicted target genes in the tumor cell lines. Our results elucidating the cross-regulations among
NF-kB, p53, and microRNAs provide insights into the complex regulatory mechanisms underlying HNSCC, and shows an
efficient approach to inferring gene regulatory programs in biological complex systems.
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Introduction
Transcriptional regulation of genes is governed by a combina-
torial operation of multiple transcription factors (TFs) and
microRNAs (miRNAs) at transcriptional and post-transcriptional
levels. These factors can organize regulatory modules and thereby
control expression of a set of genes in networks that carry out a
variety of functional processes. Therefore, identification of
regulatory modules and gene networks is critical for understanding
molecular mechanisms of transcriptional regulation in complex
biological systems. Various mathematical algorithms or computa-
tional methods have been developed for integrative analysis of
microarray gene expression and TF binding data to predict target
genes of TFs, such as Bayesian hierarchical network [1], Bayesian
multivariate modeling [2], matrix decomposition [3] and regres-
sion model [4]. Based on predicted target genes of multiple TFs,
we can unravel transcriptional regulatory modules and reconstruct
gene networks. Among these methods, matrix decomposition was
demonstrated to dissect regulatory relationships between TFs and
genes in biologically complex systems. Statistically, this is a typical
sparse matrix decomposition problem [5]. Several matrix decom-
position methods, such as probabilistic sparse matrix factorization
(PSMF), ModulePro and non-negative matrix factorization (NMF)
have been implemented for regulatory network reconstruction
based on the constraints of sparseness, non-negativeness, or partial
network connectivity information [3,6,7]. Although these methods
show improved results in uncovering biologically meaningful
regulatory programs than the decomposition methods without
these constraints, they are typically utilized separately, and no
integrative framework has been utilized to bring the sparseness
and pre-knowledge of regulator-target interactions together during
matrix decomposition [3,6,8]. Here, we devised an integrative
methodology, based on regulatory component analysis modeling,
for inferring gene regulatory networks and uncovering transcrip-
tional modules. The model-based method performs matrix
decomposition under the joint constraints of sparseness and
information of regulator-target connectivity, and allows an
integrative analysis of gene expression profile and regulator
binding data. In this method, the activity profiles of TFs or
miRNAs are first constructed from the expression profiles of their
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target genes. The regulatory components are then derived by
projecting gene expression data onto a sparse space of the
regulator activity profiles, which should reveal quantitative
relationships for regulatory network reconstruction and transcrip-
tional module discovery. The clustering of TFs or miRNAs based
on the regulatory components provides further clues for combi-
national roles of these regulators important for condition-specific
gene regulation.
Here we utilized this newly developed method to analyze the
complex regulatory networks of HNSCC. HNSCC represents
95% of head and neck cancers and is the sixth most common
malignant tumor worldwide [9]. The development of HNSCC is
associated with aberrant gene expression, which leads to diverse
phenotypic alterations and could be regulated by multiple TFs or
miRNAs. Among them, p53 and NF-kB play critical roles to
modulate cellular proliferation, apoptosis, proinflammation, and
therapeutic resistance [10,11,12]. As a tumor suppressor, p53 is
implicated as a master regulator of apoptosis, cell cycle and DNA
repair [13]. Mutations of p53 gene TP53 have been observed in
more than 40–50% of human solid tumors, including HNSCC
[14]. Our previous promoter analysis has revealed a reciprocal
relationship between p53 and NF-kB with two distinct over-
expressed gene clusters in HNSCC [15]. In a systems biology
study, we have also identified 748 potential NF-kB target genes
that are functionally associated with HNSCC by using an
integrative model COGRIM [16]. NF-kB and related signaling
pathways have served as potential biomarkers and therapeutic
targets for HNSCC and other human cancers [17,18,19].
Together with investigations from our and other laboratories, we
have shown that p53 and NF-kB are critical regulatory
determinants of multiple gene expression programs, interacting
pathways, and malignant phenotypes of HNSCC [15,20,21]. In
addition, other cancer-related TFs, such as AP1, STAT3, EGR1,
CEBPB and SP1, have been experimentally and individually
studied in HNSCC and other cancers [15,22,23,24,25,26], and
implicated in complex cross-talk with p53 or NF-kB pathways
[22,26,27,28,29,30]. However, the global modulation of gene
expression by these TFs that control development and progression
of HNSCC is not adequately understood. Moreover, alterations of
miRNAs, such as oncogenic mir21, are well-documented for
targeting p53 and NF-kB pathways [31,32]. Tumor suppressor
mir34 family (consisting of a, b and c) are direct transcriptional
targets of p53 [33]. It remains unclear whether the altered
miRNAs play as co-regulators to interact with transcriptional
modulation by TFs, especially NF-kB and p53 in HNSCC.
In this study, we applied the newly developed method to identify
transcriptional and post-transcriptional regulatory programs by
combining TF or miRNA binding data and differentially
expressed gene profiling in HNSCC cells. Our studies demonstrate
that two master TFs NF-kB and p53 have a substantial impact on
expression profiles of gene programs, including previously known
NF-kB or p53 targets, or newly predicted ones. In addition, we
defined two broader transcriptional regulatory programs of seven
key TFs, including NF-kB, p53, AP1, CEBPB, EGR1, SP1 and
STAT3. Furthermore, we reverse engineered regulatory networks
of NF-kB, p53, mir21 and mir34ac in HNSCC cell lines and
tissues, respectively. Our findings indicate that NF-kB, p53 and
the miRNAs form concerted regulatory modules in the progression
and metastatic program of HNSCC. We validated the target genes
of NF-kB and p53 identified by the model-based method by
silencing of the two TFs and testing p53 binding activity on
promoters. Our results not only unveil predominant roles of NF-
kB and p53 transcriptional regulation in affecting the gene
expression of different HNSCC phenotypes, but also provide a
framework for future experimental analysis of miRNA regulatory
functions.
Materials and Methods
Microarray datasets
The microarray data were from ten HNSCC (UM-SCC:
University of Michigan series of HNSCC) cell lines and four
human normal keratinocytes [15,34]. Tumor lines were divided to
two subgroups, the mutant (mt) p53 and wild type (wt) p53-
deficient cells that contain intact wtp53 genotype but expression is
very low [15,34]. We identified differentially expressed genes
among the human normal keratinocytes and the HNSCC
subgroups that satisfied $2.0 fold change of gene expression of
either subgroup with the mt p53 or the wt p53-deficient status
when compared with gene expression in the normal keratinocytes.
In addition, two gene expression microarray datasets of HNSCC
metastatic and non-metastatic tissues (accession numbers
GSE2280 and GSE2379) were retrieved from the Gene Expres-
sion Omnibus (GEO) database at the National Center for
Biotechnology Information (NCBI).
TF and miRNA binding data
Binding data of nine TFs (RelA, cRel, NFkB1, p53, AP1,
CEBPB, EGR1, SP1 and STAT3) and two miRNAs (mir21 and
mir34ac) were extracted from previous publications or predicted
conserved binding sites (see Text S1 for the detailed information).
The model-based method and application in HNSCC
We devised a novel method for identifying target genes of
regulators and inferring gene regulatory networks. The method is
based on regulatory component analysis modeling, performing
matrix decomposition under the joint constraints of sparseness and
partial information of regulator-target connectivity. It allows an
integrated analysis of gene expression profiles with binding data of
a set of regulators (such as TFs, miRNAs, etc.).
The newly developed method is a network structure-driven
model for inferring gene regulatory networks and uncovering
regulatory modules. Given a microarray data matrix X[<N|M
with the sample size M and the numbers of genes N, our aim is to
find Y[<N|L and Z[<L|M such that the square error (Euclidean
distance) function:
E(Y ,Z)~ X{YZk k ð1Þ
is minimized under a desired degree of sparseness on the mixing
matrix Y. We defined a sparseness measure S(yl) based on the
relationship between the L1 norm and the L2 norm [35]:
S(yl)~
ffiffiffiffi
N
p
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where yl~½y1ly2l    yNl T is the lth column of Y, and the
superscript ‘‘T’’ means ‘‘transpose’’. The L1 norm Dyl D1 and the L2
norm Dyl D2 were defined as Dyl D1~
XN
i~1
Dyil D and
Dyl D2~
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiXN
i~1
y2il
r
, respectively. The sparseness evaluates as one
if, and only if yl contains a single non-zero element, and takes a
value of zero if and only if all elements are equal.
The rows of Z represent the expression profiles of the L latent
variables across samples, and can also be viewed as the activity
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profiles of the L regulators. Thus, we can cluster genes based on
corresponding non-zero coefficients of Y, which represent gene
regulatory programs, i.e. regulatory modules that are co-regulated
by the L regulators. In the new method, we developed an iterative
learning algorithm that is capable of combining constraints of
sparseness and limited information of regulator-target binding.
The sparseness was used as a statistical parameter for modeling the
regulatory components of TFs or miRNAs and their targets. The
learning procedure was based on a projected gradient descent
approach with sparseness constraints [35].
To run the model, two inputs are required: 1) microarray data
matrix X and 2) regulator binding data matrix C. C can be
constructed from Chromatin Immunoprecipitation (ChIP)-based
(such as ChIP-seq and ChIP-chip) data, known regulator-target
binding, or the promoter sequence analysis of conserved binding
sites, etc. In general, there are five steps for the procedures:
Step 1: Initial Y to a random matrix.
Step 2: Construct Z. For inferring gene regulatory network,
estimate Z from X and C based on the median of
expression values.
Step 3: Project each column of Y to have unchanged L2 norm,
and L1 norm set to achieve a desired sparseness.
Step 4: Update Y through iteration.
a) SetY :~Y{m(YZ{X)ZT, m is the given step size.
b) Project each column of Y to have unchanged L2
norm, and L1 norm set to achieve a desired
sparseness.
c) If X{YZk k2we, continue iteration; else stop.e is
the given convergence criterion.
Step 5: Reconstruct regulatory network/gene modules. Mod-
ule_l: = (geneID [i], satisfyyil=0, for i~1,    ,N and
l~1,    ,L). yil is the element of YModule. l represents
lth transcriptional module regulated by the TF l or the
latent regulator l.
The output (Y matrix) of the procedure provides quantitative
relationships between regulators (TFs and miRNAs in this study)
and every gene from the microarray dataset. The non-zero values
stand for regulatory interactions or components which can be used
to estimate how possible a gene is regulated by the regulators or
whether a gene is potential target of the regulators. To select the
putative target genes, we re-evaluated Y matrix by including
following criteria. We first performed 1000 runs by using
randomly selected regulator-target binding data as inputs. The
target genes of such regulator binding were randomly picked up
from their corresponding microarray dataset during the model
running. The 1000 randomly selected regulator binding data were
used to construct Z matrices and generated new Y matrices
following the same procedure, respectively. We then calculated P
value of each gene in the original Y matrix created by using
regulator binding data based on pre-knowledge or by promoter
sequence analysis in comparison with the new Y matrices. In
general, the majority of top genes in the original Y matrix have a
lower P value. We selected genes with the top values or containing
lower P values in the original Y matrix and identified them as
putative target genes of TFs. The code of the model is available
upon request.
We applied the model-based procedure to analyze HNSCC
gene expression profile, TF and miRNA binding data, and
reconstructed regulatory networks of HNSCC (see Table S1). The
gene expression dataset (X matrix) was derived from microarray
data of genes differentially expressed in HNSCC cells with the wt
p53-deficient or the mt p53 status. We sought to unravel TF and
TF-miRNA mediated regulatory networks responsible for the
malignant phenotypes of HNSCC. Nine TFs were examined in
this study: RelA, NFkB1, cRel, p53, AP1, CEBPB, EGR1, SP1
and STAT3, which were chosen because of their possible
interactions with NF-kB family subunits or p53. In addition, we
applied the model to analyze target genes of mir21 and mir34ac by
integrating their binding data. Since the different tumor subgroups
display distinct gene expression patterns cross all samples, we
separated genes into four subsets: differentially over and under-
expressed gene sets for wt p53-deficient and mt p53 subgroups,
respectively. Through the analysis, we constructed four regulator-
target binding activity matrices (Z matrix) for the regulators
according to the corresponding gene expression profile of the
subsets, respectively. Consequently, each Y matrix for TFs or
miRNAs of the four gene subsets was calculated based on their
corresponding Z matrix and expression data. Finally, we identified
TF and miRNA regulatory modules which control different gene
expression programs in HNSCC cell lines and tissues.
Knocking down RelA and TP53 by siRNA
The knockdown of RelA and TP53 mRNA was performed by
using siRNA (ON-TARGET plus SMARTpool; Dharmacon,
Lafayette, CO). UM-SCC 1 (wt p53-deficient) and 22B (mt p53)
cells were seeded in 6-well plates at 16105/well. At 50–60%
confluency (24 h later), cells were transfected with 50 nM of a
mixture of four siRNA oligos directed against human RelA, or
TP53 designed by Dharmacon, or 50 nM of a non-silencing
control siRNA (QIAGEN, Valencia, CA), using 1:200 Lipofecta-
mine 2000 (Invitrogen, Carlsbad, CA) in Opti-MEM I Reduced
Serum Medium (Invitrogen, Carlsbad, CA) for five hours. At 48 h
or 72 h post-transfection, cells were harvested in Trizol for RNA
isolation (Invitrogen, Carlsbad, CA).
Real time RT-PCR
RNA isolation and cDNA synthesis were performed as
previously described [36]. Real time PCR primers and probes
for DNp63 [36] were synthesized by Applied Biosystems (Foster
City, CA). Other primers and probes were purchased through
Assays-on-DemandTM program from Applied Biosystems. Ampli-
fication conditions were: 2 min at 50uC and 10 min at 95uC,
followed by 40 cycles of 15 sec at 95uC and 1 min at 60uC, carried
out using an ABI Prism 7700 Sequence Detection System (Applied
Biosystems). Relative gene expression values were calculated after
normalization to 18S rRNA, and adjust the value of the control
sample as 1. Each experiment was done in duplicates, and each
sample was assayed in triplicates. Data were presented as mean +
standard deviation (SD).
p53 DNA binding assays
p53 DNA binding activity was quantitatively assessed using a
modified version of the TransAM p53 ELISA kit from Active
Motif (Carlsbad, CA). The regular oligonucleotide-coated 96-well
plate was substituted with a streptavidin-coated plate and cus-
tom 59-biotinylated double-stranded oligonucleotides containing
known or putative p53 binding sites were added (IDT, Coralville,
IA) to the assay. Each binding site was approximately 20–30 bp
and flanked by 30–40 bp of native sequence upstream and 7 bp
downstream. The sequences for the forward strand of each
double-stranded oligonucleotide were as follows: IL6: 59 biotin-
TAGGCTTGGCGATGGGGTTGAAGGGCCCGGTGCGCA-
TGCGTTCCCCTTGCCCCTGCGTGT -39 (sequences under-
lined refer to core consensus binding sites of p53 predicted by
Regulatory Networks in Head and Neck Cancer
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Genomatix MatInspector); SERPINE1: 59 biotin-ATTCTCCTG-
CCTCAGCCTCCCAAGCAGCTAGGATTACAGGCACGCA-
CCACCATGCCTAGCTGATTT-39; MMP1: 59 biotin-ATTA-
ACTCACCCTTGTTTCCCAGGCCTCAGTGGAGCTAGGC-
TTGTCACGTCTTCACAGTG -39; PLAU: 59 biotin- AGCT-
GCGGGCAAGGGGGTCTGAGGCAGTCTTAGGCAAGTT-
GGGGCCCAGCGGGGAGAAGT -39; CDKN1A (p21): 59biotin-
GCAGGCTGTGGCTCTGATTGGCTTTCTGGCCGTCAG-
GAACATGTCCCAACATGTTGAGCTCTG -39, where p53
binding site on CDKN1A promoter is known. Other reagents
from the kit (buffers, antibodies, and substrates) were used as is.
Nuclear lysates containing p53 protein were obtained from
UM-SCC 1 cells overexpressing p53. The cells were transfected
with p53 plasmid using Lipofectamine, per the manufacturer’s
protocol (Invitrogen, Carlsbad, CA). After 48 hours, nuclear
protein was isolated using a nuclear extract kit (Active Motif,
Carlsbad, CA, USA). The protein concentration was determined
using the BCA method (Pierce, Rockford, IL, USA). The 5 mg of
nuclear extract in cell lysis buffer and complete binding buffer and
1 pmol of biotinylated oligonucleotide were combined and
incubated for 30 min at room temperature prior to placement in
a streptavidin-coated well. Specificity of binding was also tested
using cold competition (unbiotinylated) oligonucleotides which
contained the p53 consensus binding sequence (‘‘wt competition’’)
or non-mammalian DNA (‘‘mt competition’’) at 40 pmol/well,
added to the reaction at room temperature prior to plating. These
competition oligonucleotides had a 10 bp core sequence flanked
by 7 bp of non-specific sequence both upstream and downstream
of the consensus motif. Nuclear extract from MCF-7 cells (a
human breast adenocarcinoma cell line) (Active Motif) combined
with a biotinylated oligonucleotide containing a known p53
binding site in the CDKN1A gene promoter (‘‘MCF-7 p21 oligo’’)
served as a positive control (Active Motif). Wells containing only
the ‘‘p21 oligo’’ biotinylated oligonucleotide and no cell lysate
served as the negative control. Each binding site was assayed in
duplicated. After developing the final HRP-mediated colorimetric
reaction for 2–3 min, absorbance was measured at 450 nm by
mQuant ELISA microplate reader (Bio-Tek, Winooski, VT, USA).
Results
The model-based approach to determine the interactions
between TFs or miRNAs and target genes
We present a novel bioinformatics method for an integrative
analysis of regulators (TFs and miRNAs) and gene expression
profiles in HNSCC. An important feature of the method is its
capacity to combine diverse data sources and perform matrix
decomposition with sparseness constraint by regulatory compo-
nent analysis. This integrated analysis offers an opportunity to
infer regulatory components, which profile the interactions of each
regulator with all the genes. The inferred interaction between
regulators and their targets are condition specific, depending on
the projection of condition specific expression data to the sparse
and non-negative space of latent variables (regulators).
Figure 1. Overview of the regulatory component analysis model-based method. R: regulators (TFs, miRNAs). TG: target genes. TSS:
transcriptional start site. 39UTR: 39 Translated region. Nodes in red and green represent up and down-regulated target genes, respectively.
doi:10.1371/journal.pone.0073656.g001
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Figure 1 outlines the approach based on regulatory component
analysis modeling. First, two input data matrices are required: the
microarray profile of gene expression (X matrix, N genes 6 M
samples) and regulator-gene connectivity matrix (N genes 6 L
regulators). The connectivity between a regulator (TF or miRNA)
and a gene is set to 1 if there is binding between the regulator and
the gene in the microarray datasets, or set to 0 otherwise. Second,
the regulator activity profile (Z matrix, L regulators6M samples)
of each regulator is constructed by integrating the expression
profile and the regulator-gene connectivity. The regulator activity
profile represents the expression pattern of each regulator across
all samples, determined by the median of expression values. Third,
the Y matrix (N genes6 L regulators) is generated according to
[X] = [Y]?[Z], where contains quantitative relationships for
each regulator-gene pair. Each column of Y matrix represents a
regulatory component, derived by projecting gene expression data
onto a sparse space of the regulator activity profiles. The Y matrix
allows determining whether a gene is potential target of a
regulator, i.e. TF or miRNA. Ideally, Y matrix can capture non-
zero regulatory components between regulators and their target
genes. Such regulatory components provide a basis for recon-
structing regulatory networks through unsupervised learning, or
can be used to cluster genes into regulatory programs or networks.
Therefore, in the final step, such gene regulatory programs or
networks are identified, and then classified to biological functions.
The inferred programs or networks are sets of genes co-regulated
by multiple TFs or miRNAs known or hidden.
Using the newly developed method, we first identified putative
target genes of the nine TFs and their gene regulatory programs.
We found that our method is able to dissect regulatory interactions
between TFs and their target genes in HNSCC, and performed
better when compared to the COGRIM method that was
previously used [16]. The COGRIM method is based on a
Bayesian hierarchical model and Gibbs sampling implementation,
and predicts regulatory modules by an integrative analysis of
microarray gene expression and TF binding motif data [1]. We
compared our method to COGRIM to predict target genes by
using the same microarray datasets based on a Gene Ontology
(GO) analysis of the target genes of the three NF-kB subunits,
RelA, NFkB1 and cRel. We assessed the functional relevance of
GO biological processes based on the enrichment analysis by
Fisher’s exact tests. Table 1 shows the statistical enrichment of
biological processes among the target genes identified by the two
methods. The enrichment level was calculated by transforming the
enrichment P values after False Discovery Rate (FDR) correction
to negative log10 values and averaged over all biological processes
with corrected P,0.05. If no functional modules were found with
corrected P,0.05, the smallest value of corrected P was taken for
calculating the enrichment level. Overall, our method showed a
better performance than COGRIM. The averaged P values of
over-representation and FDR values were lower than COGRIM
in both wt p53-deficient and the mt p53 datasets. With the
exception of NFkB1 targets in the wt p53-deficient dataset, our
method in general displayed lower corrected P values of FDR
(Table 1). The comparative analysis indicates that our method can
lead to a more biologically meaningful prediction of TF target
genes and regulatory programs.
Prediction of HNSCC-specific target genes of TFs
Our analysis predicted 248 target genes of NF-kB in the wt
p53-deficient cells of HNSCC, which include 149 over- and 99
under-expressed genes (Figure 2A). These genes were putatively
targeted by at least one of three NF-kB subunits, i.e. RelA, NFkB1
or cRel, representing 51% and 20% of differentially over and
under-expressed subsets, respectively. Thus, a majority of the
predicted NF-kB targets are up-regulated in the wt p53-deficient
cells, consistent with the previous observation that NF-kB binding
dominates the promoters of over-expressed genes in the same type
of HNSCC cells [15,34]. Among all the predicted target genes, 28
over- and 32 under-expressed genes were common targets of all
the three NF-kB subunits. On the other hand, in the mt p53 cells,
we predicted a set of 418 NF-kB targets, which represent 40% and
56% of the differentially over- and under-expressed gene sets,
respectively (Figure 2A). A set of 62 genes were jointly targeted by
the all three subunits of NF-kB, among which 19 genes were over-
while 43 were under-expressed. Within all the predicted NF-kB
target genes from the two tumor subgroups, 83 are identical to
known NF-kB targets.
To discover HNSCC-specific p53 targets, we incorporated
known binding data for p53 (see Materials and Methods) and the
gene expression profiling data. The analysis identified 169 and 81
putative p53 target genes from the wt p53-deficient and the mt p53
subgroups, respectively (Figure 2A). The two subgroups shared 7
over- and 22 under-expressed target genes, indicating more
common p53 genes are down-regulated in tumor cells. In total, 36
genes of the total predictions are consistent with known p53
targets, while others are novel candidates. These predicted p53
targets could be annotated to GO biological processes that are
similar to those mediated by NF-kB gene programs.
To identify gene regulatory programs of multiple TFs, we first
constructed two networks linking each TF and their putative
targets predicted in the two tumor subgroups (Figure S1). A total
of 298 and 232 genes were identified as common targets of at least
two TFs in the wt p53-deficient and the mt p53 cells, respectively.
We then compared target genes of NF-kB or p53 with other five
TFs (AP1, CEBPB, EGR1, SP1 and STAT3). Table S2 shows the
numbers of overlapped target genes. We detected significantly
overlapped target genes between NF-kB or p53 and the other TFs
in three gene subsets except for the over-expressed wt p53-
deficient cells. In this subset, we detected significant overlaps of
Table 1. Comparison based on GO functional enrichment.
p53
type a TFs Over-representation
b FDR c
Our
method COGRIM
Our
method COGRIM
wt RelA 5.08 4.81 1.92 1.81
NFkB1 3.89 4.04 1.66 1.7
cRel 3.41 2.93 1.59 1.08
Average
of TFs
4.13 3.93 1.72 1.53
mt RelA 3.86 3.09 1.8 0.89
NFkB1 3.23 3.63 1.65 1.55
cRel 3.69 3.29 1.74 1.42
Average
of TFs
3.59 3.34 1.73 1.29
All predicted target genes of three NF-kB subunits were used for GO functional
analysis. The enrichment level was calculated by transforming enrichment P
values averaged over all processes with False Discovery Rate (FDR) corrected
P,0.05. If no processes are found with corrected P,0.05, the smallest value of
corrected P was taken for calculating the enrichment level. a p53 type refers to
subgroups of HNSCC cell lines divided by p53 mutation: wt p53-deficient and
mt p53. b enrichment of Fisher exact P value after negative log10
transformation. c FDR correction to the negative log10 value.
doi:10.1371/journal.pone.0073656.t001
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target genes between NF-kB or p53 and three TFs CEBPB, EGR1
and STAT3. Although not statistically significant, 53–58% of the
target genes of p53, AP1, and SP1 were overlapped with the NF-
kB targets. Our analyses provide evidence that NF-kB or p53
interact with the other five TFs to commonly regulate gene
expression programs in HNSCC cells.
Notable was that all p53 target genes predicted in the mt p53
cells were also NF-kB targets (Figure 2A), whereas those
overlapping in the wt p53-defficent cells was 60% (P
,2.04610218, R=1.9). Specifically, the intersection of target
genes between p53 and the three NF-kB subunits was also
significant in the same three gene subsets (Table S2). On the other
hand, we noted that a fraction of the NF-kB target genes
overlapped with p53 targets seems different between the wt and mt
p53 subgroups. Among the total NF-kB target genes, 41% were
overlapped with the p53 targets in the wt p53 deficient, which was
greater than those in the mt p53 cells (19%). This difference is due
to the different fractions of their overlapped genes observed in the
under-expressed gene subsets (61% vs. 16%), suggesting that most
of NF-kB down-regulated genes are targeted by p53 in the wt
p53-deficient cells. We did not find such a difference in the over-
expressed gene subsets (28% vs. 24%). Next, we annotated co-
targets of NF-kB and p53 to gene ontology (GO) biological
processes (Table S3A). The top enriched processes in the both wt
and mt p53 cell lines included regulation of key functional
processes important in cancer, such as proliferation, angiogenesis,
apoptosis, inflammatory responses, and cell migration. Further-
more, we identified significantly enriched canonical signaling
pathways (P,0.05) using the Ingenuity Pathway Analysis (IPA)
tool. As shown in Table 2, fifteen pathways, including Ephrin
receptor, ERK/MAPK, HGF, IGF-1, IL-6, IL-8, Integrin linked
kinase, Integrin, Neuregulin, p38 MAPK, p53, PI3K/AKT,
PPAR, PTEN, and TREM1 were enriched in the both tumor
subgroups. Most genes in the pathways were down-regulated
(Table S3B). CDKN1A, IL6, PTK2, PTGS2 and TP63 are known
target genes of both NF-kB and p53.We also detected 14–3–3-
mediated, HIF1a, Leukocyte extravasation, mTOR, NF-kB,
TGFb, VEGF, and Xenobiotic metabolism signaling enriched in
the wt p53-deficient subgroup. The majority of genes in the eight
pathways were also down-regulated (Table S3B). In contrast, four
enriched pathways, CDK5, HER-2 in breast cancer, Protein
kinase A, and Small cell lung cancer signaling, were observed in
the mt p53 subgroup. This analysis provides evidence that NF-kB
may interact predominantly with p53 in mediating distinct or
common pathways in tumor cells with different p53 status.
Finally, we defined two regulatory programs consisting of
common target genes of all the seven TFs (Figure 2B). The
program of the wt p53-deficient cells comprised 37 genes, where
17 and 12 genes are consistent with known NF-kB and p53 targets,
respectively. The percentage of known NF-kB and p53 target
genes in the network was greater than their overall prediction (for
example, NF-kB: 46% vs. 19%; p53: 32% vs. 15%). Similarly, a
set of 39 genes, including 12 known NF-kB and 17 known p53
targets, formed the regulatory programs of the mt p53 cells. The
prediction of the known target genes in the program was also
relatively accurate by comparing with the overall prediction for
NF-kB (31% vs. 15%) and p53 (44% vs. 29%) target genes. In the
both transcriptional regulatory programs, 10 target genes were
Figure 2. Transcriptional gene regulatory programs in the HNSCC cell lines. A, Overlapped target genes of NF-kB and p53. B, Gene
regulatory programs of seven TFs (NF-kB, p53, AP1, CEBPB, EGR1, SP1, and STAT3). Genes in underlined, bold and bold-underlined refer to known
targets of NF-kB, p53, and both NF-kB/p53, respectively.Q andq refer to number of predicted target genes differentially over- and under-expressed
in the tumor cells, respectively.
doi:10.1371/journal.pone.0073656.g002
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shared between the two subgroups of HNSCC (Figure 2B).
Furthermore, we found that most genes in the regulatory
programs were functionally classified to adhesion, angiogenesis,
apoptosis, cell cycle, inflammatory and immune responses,
proteolysis, and regulation of transcription. This indicates that
the HNSCC-specific gene programs of the seven TFs can mediate
broad functional processes.
miRNA target genes and their interaction with NF-kB and
p53
mir21 and mir34ac are known for their relationships with the
p53 or NF-kB pathway. We applied the model-based approach to
analyze their target genes and determine how many of these genes
are co-targeted by the two TFs using the same gene expression
profile of HNSCC cell lines. Table S4 lists the predicted targets of
the two miRNAs overlapped with that of NF-kB and p53. We
identified 73 and 84 target genes of mir21 and mir34ac in the wt
p53-deficient cell lines, respectively. They displayed a highly
frequent intersection (56–77%) with target genes for the two TFs.
Compared with miRNA databases TarBase and mir2disease,
besides the known binding targets, some predicted genes are likely
regulated by mir21or mir34ac based on other validation methods
such as qRT-PCR, microarray, proteomics and Western blot
analyses. For example, CDKN1A, PIK3R1, RHOB, TGFB1 and
THBS1 are possible targets of mir21; and EHD1, NDRG1, S100A2,
and SFN are likely targets of mir34ac. Moreover, we compared our
results with those predicted by software package miRecords, which
provides eleven computational methods for miRNA binding target
search [37]. Totally 16 and 31 target genes of mir21 and mir34ac
in our prediction were identified by at least three methods
respectively (Table S4). Similarly in the mt p53 cell lines, the new
model predicted 76 and 77 target genes of mir21 and mir34ac,
respectively, whereof 63–88% are also targets of the two TFs. By
searching miRecords, we also found that 15 targets of mir21 or 29
targets of mir34ac can be detected by at least three computational
methods (Table S4).
We constructed gene networks composed of co-targets of NF-
kB, p53, mir21 or mir34ac in the two types of tumor cells. There
are 17 common genes presented in the two networks (Figure 3). In
the network of the wt p53-deficient (Figure 3A), we identified
several known targets of miRNAs, such as BTG2, JAG1,
SERPINB5, and TP63 for mir21, and ACSL1 and JAG1 for
mir34a. The network of the mt p53 includes known targets of
mir21 (SERPINB5 and TGFBR2) and mir34ac (ACSL4 and MYC,
Figure 3B). This result highlights a considerable interaction of NF-
kB and p53 with the two miRNAs for gene regulation in HNSCC
cell lines. The majority of the two networks involve in biological
functions similar to TF regulatory programs (Figure 2), such as
apoptosis, proteolysis, proliferation, cell adhesion and migration,
inflammatory and immune responses, and angiogenesis. These
cellular processes are possibly related with tumor progression and
metastasis [38,39].
We subsequently sought to construct similar networks of TF-
miRNA by analyzing gene expression profiling data from
metastatic and non-metastatic tissues in hypopharyngeal [40]
and oral cancer [41]. Table S5 lists all overlapped target genes
among NF-kB, p53 and the two miRNAs. We constructed two
networks consisting of 26 and 43 target genes of the four regulators
in the two types of tumor tissues, respectively (Figure 4). By
comparison with the cell line networks (Figure 3), 12 and 13
intersected genes in the networks of two types of HNSCC tissues
were observed respectively. Also, biological functions in these gene
networks are similar, supporting the consistence between cell lines
and tissues to some extent. Moreover, we identified about a half of
genes which are known targets of NF-kB or p53 in the both
networks. For example, IL6, PTX3, BCL2, FAS, FOS, IER3, PTX3,
SERPINE1, and TP63 were known to be co-regulated by the two
TFs. Interestingly, apoptotic regulator BCL2 is a known target of
both mir21 and mir34ac (Table S5). Our findings indicate that
both mir21 and mir34ac likely involve or interact with NF-kB and
p53 networks through their downstream genes underlying tumor
progression.
Validation of p53 and NF-kB target genes by siRNA
knockdown and promoter binding assay
We selected the identified selected cancer-related target genes
with potentials under p53 and NF-kB regulation in the networks
from Figure 3, and tested whether their expression can be affected
by siRNA knockdown of either TP53 or NF-kB RelA/p65. As
shown in Figure 5A or 5B, there are eight panels each representing
eight potential target genes for TP53 or NF-kB from our
bioinformatics prediction. The siRNA knockdown experiments
were performed in two cell lines, one is UM-SCC 22B with mt p53
(Y220C) but remaining residual p53 binding activity (Figure 5A),
and other is UM-SCC 1 with deficient wt p53 status [42]
(Figure 5B). The deficient wt p53 status was defined as wild type of
p53 genotype but minimal p53 protein expression and binding
activity [42]. In each panel, the open bar represents the cells
transfected with control siRNA, for which the value has been
normalized to 1 to enable comparison. Black bars represent cells
transfected with siRNA to knockdown TP53, and the blue bars
represent cells transfected with siRNA to knockdown NF-kB
subunit RelA/p65. The relative expression after either knockdown
of TP53 (black bar) or RelA/p65 is presented as the fold increase
or decrease when compared with cells transfected with control
siRNA (open bar). In this experiment, previous experimentally
validated known target genes of p53 (CDKN1A and IGFBP3) and
NF-kB (IL6 and IL8) are included as positive controls. * indicates
statistical significance when compared the gene expression after
knockdown of TP53 or RelA/p65 with those from cells transfected
with control siRNA. As shown in Figure 5A, after knocking down
Table 2. Enriched signal pathways in the gene regulatory programs of NF-kB and p53.
HNSCC cell
lines Enriched signaling pathways
mtp53 CDK5, HER-2 in breast cancer, Protein kinase A, Small cell lung cancer
wt p53-deficient 14–3–3-mediated, HIF1a, Leukocyte extravasation, mTOR, NF-kB, TGFb, VEGF, Xenobiotic metabolism
mt and wt p53 Ephrin receptor, ERK/MAPK, HGF, IGF-1, IL-6, IL-8, Integrin linked kinase, Integrin, Neuregulin, p38 MAPK, p53, PI3K/AKT, PPAR, PTEN, TREM1
Canonical pathways in the table were significantly enriched (P,0.05) among the regulatory programs consisting of common target genes between NF-kB and p53.
doi:10.1371/journal.pone.0073656.t002
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of TP53 or RelA in UM-SCC 22B cells (mt p53) for 48 hours, the
expression level of TP53 or RelA was dramatically reduced by
more than 80%, when compared to control siRNA (the upper left
two panels). These two panels exhibited the specific and efficient
knock down of TP53 or RelA/p65 genes. Knocking down TP53
(black bar) increased the expression of IGFBP3, suggesting that p53
mediated suppression of the expression of this gene (upper left
third). Silence of TP53 (black bars) slightly decreased the
Figure 3. Gene regulatory networks of NF-kB, p53, mir21 and mir34ac in the HNSCC cell lines. A, network of the wt p53-deficient cells. B,
network of the mt p53 cells. Every node represents a common target gene of NF-kB, p53, mir21 or mir34ac, and was annotated according to
inflammatory and immune responses (green nodes), apoptosis (blue), angiogenesis (yellow), proliferation (red), adhesion (gold), proteolysis (light red)
and other processes (light blue). The networks were presented by cytoscape.
doi:10.1371/journal.pone.0073656.g003
Figure 4. Gene regulatory networks of NF-kB, p53, mir21 and mir34ac in the HNSCC metastatic tissues. A, a network of hypopharyngeal
cancer. B, a network of oral cancer. Every node represents a common target gene of NF-kB, p53, mir21 or mir34ac, and was annotated to
inflammatory and immune responses (green nodes), apoptosis (blue), angiogenesis (yellow), proliferation (red), adhesion (gold), proteolysis (light red)
and other processes (light blue). The networks were presented by cytoscape.
doi:10.1371/journal.pone.0073656.g004
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expression of IL6, ITGA5, LAMB3, PLAU, and CDKN1A in UM-
SCC 22B cells with statistical significance. This could be explained
by its mt p53 status with residual function, or as suggested by other
findings, that a group of loss of function p53 mutants have gained
the ability to interact and promote the transcription of other TFs,
including NF-kB, which could promote tumorigenesis [43,44].
After knocking down RelA/p65 (Figure 5A, blue bars), most genes
were significantly decreased, except IGFBP3, which is consistent
with NF-kB activation in the cells. Figure 5B showed the
knockdown experiments in UM-SCC 1 cells with wt p53
genotype, but where expression of p53 is barely detectable.
Further knocking down of TP53 (black bars) significantly increased
the expression of IL8, ITGA5, TNC, MMP1, SERPINE1, and
DNp63, but reduced the expression of IL1RN and PLAU. Our data
suggest that the low level of wt p53 protein expression in the cell
line is still functional. The data is consistent with previous findings
from our and other laboratories, that p53 protein is extremely
powerful to regulate gene expression [36,44]. Knockdown of RelA
(blue bars) decreased expression of IL8, ITGA5, IL1RN and PLAU
but resulted in an increase in the expression of TNC, MMP1,
SERPINE1 and DNp63 (Figure 5B), which are consistent with our
predictions as NF-kB target genes.
Previously, we analyzed binding activity of NF-kB subunits
RelA and NFkB1 in three UM-SCC cell lines using TransAM NF-
kB oligonucleotide-ELISA binding assay from Active Motif [16].
Here we examined binding activity of p53 on the promoters of its
target genes identified in this study, using the newly modified p53
oligonucleotide-ELISA binding assay, based on TransAM p53
ELISA from Active Motif. In this modified assay, p53 binding
consensus sequence was replaced by different promoter sequences
with predicted p53 binding sites (detailed information in Methods).
We used MCF-7 cell lysate as the positive control, which was
provided by Active Motif. We used an oligo containing a known
p53 binding site in the CDKN1A promoter (‘‘MCF-7 p21 oligo’’, in
Figure 6) for a positive control [45]. This oligonucleotide contains
a 63-bp sequence containing known p53 binding motif, which has
been validated previously by Electrophoretic Mobility Shift Assay
(EMSA) and ChIP binding assay result of CDKN1A/p21 promoter
[20]. Since we previously showed that UM-SCC 1 (wt p53
deficient) and UM-SCC 22B (mt p53) exhibited minimal p53
binding activity [42], we overexpressed wt p53 in UM-SCC 1 cells
to test p53 binding activity for the predicted p53 binding motifs on
the promoters of less studied p53 targeted genes using Genomatix
MatInspector. We found strong p53 binding activities on predicted
p53 sites on CDKN1A, SERPINE1, IL6, PLAU and MMP1
promoters (Figure 6). Using excess p53 wild type (wt) oligo in
the binding assay, we were able to compete off the binding activity,
while the mutant (mt) oligo did not compete off the binding
activity, demonstrating the binding specificity (Figure 6). Our
experimental data confirmed the predicted binding motifs of the
new p53 target gene.
Discussion
Our method is regulatory component analysis model-based and
can capture the sparse structure existing in genomic-scale gene
expression data for unraveling gene regulatory networks. The
advantage of the newly developed method is supported by the
improved prediction of NF-kB and p53 target genes, in
comparison with other methods. First, we compared our method
to a Bayesian model-based COGRIM. Among the NF-kB targets
predicted by our method, of 19% (in the wt p53-deficient) and
15% (in the mt p53) are consistent with known ones published
previously. By contrast, the known NF-kB genes predicted by
COGRIM only reached to 10% of the total prediction [16].
Importantly, the NF-kB genes predicted by our method are more
functionally relevant than those by COGRIM (Table 1). Second,
we analyzed the percentage of known p53 target genes in its total
prediction. Previous studies have shown that p53 binding could be
one of key elements controlling over-expression of genes in the mt
p53 cells of HNSCC [15,34]. Our analysis indicates that 10% (in
the wt p53-deficient) and 24% (in the mt p53) of the over-
expressed p53 target genes are matched with known ones, thus
partially supporting the previous finding. Some high-throughput
technologies, such as ChIP-pet [46] and ChIP-seq [47] were
utilized to detect physical binding sites of p53 on whole genomic
sequences. Wei et al. identified 542 p53 binding loci clustered in
458 known genes by using p53-ChIP DNA fragments and
overlapping pet-clusters as the readout [46]. By searching for
known p53 target genes, we found that 15% (in the wt p53-
deficient) and 29% (in the mt p53) of the total p53 targets
predicted by our method are identical, which is relatively better
than the ChIP-pet method (14%). Recently, a genome-wide
analysis of p53 binding sites in normal human IMR90 fibroblast
cells showed 743 high-confidence ChIP-seq peaks representing
956 genes [47]. We compared these putative genes with known
p53 targets, and found 52 overlapped ones, which is less than our
predication. Taken together, our method improves the efficiency
and accuracy of identification of regulatory associations between
NF-kB or p53 and their target genes. The identified NF-kB genes
by the newly developed method are highly associated with
biological processes altered in HNSCC, suggesting that they are
biologically more meaningful than those by other methods.
Two master TFs, NF-kB and p53, play different roles in human
cancer, in which activation of p53 and inhibition of NF-kB
promote apoptosis. Their crosstalk is suggested as an important
mechanism for regulating molecular oncogenesis [11]. However,
how they interact and globally modulate gene networks remains
unclear. In the present study, we demonstrate a significant
intersection between p53 and NF-kB regulated genes in the
HNSCC cell lines. Such interaction is different in the two tumor
subgroups. In the wt p53-deficient cells, the two TFs can jointly
regulate over 60% of their targets in the under-expressed genes
(Figure 2A). The two factors, along with the other five TFs (AP1,
CEBPB, EGR1, SP1 and STAT3), are implicated in modulating
90% of the under-expressed NF-kB target genes (Table S1).
However, in the mt p53 cells, all of the predicted p53 targets can
be regulated by NF-kB (Figure 2A). Significantly, the three
subunits RelA, NFkB1 and cRel cooperate with p53 to regulate
their common genes, which facilitates a wide interplay between
p53 and NF-kB networks. This observation strongly suggests that a
tight interaction between NF-kB family and p53 controls p53
networks in the mt p53 tumor cells, but to a lesser extent in the wt
p53-defieient cells. On the other hand, most (about 80%) of the
predicted NF-kB target genes in the mt p53 cells are not regulated
by p53 (Figure 2A). A half of these NF-kB genes are also not
targeted by any one of other five TFs (Table S1). Therefore, the
NF-kB genes in the mt p53 tumor cells are possibly modulated by
loss or altered of p53 function, or by means of interactions of NF-
kB with a broad arrange of TFs or miRNAs.
We identified two transcriptional gene regulatory programs that
are likely modulated by the seven TFs (Figure 2B). Previous
experimental studies on TF interactions in gene regulation support
our discovery, for example, NF-kB-AP1-CEBPB [22,27], NF-kB-
STAT3 [26], NF-kB-AP1-EGR1 [29], NF-kB-AP1-SP1 [30], NF-
kB-AP1-p53 [48], etc. In HNSCC cell lines, co-binding of RelA,
AP1 and CEBPB on IL8 promoter contributed to its over-
expression [22]. A similar result was repeated in breast cancer cells
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Figure 5. Silencing RelAandTP53 by siRNA significantly altered gene expression. UM-SCC 22B (A, the mt p53) and 1 (B, the wt p53-deficient)
cells were transfected with siRNA to RelA or TP53 for 48 h or 72 h. Total RNA was isolated, and genes selected from TF-miRNA networks in the Figure 3
were analyzed by real time qRT-PCR. The data were calculated as the mean plus standard deviation from triplicates with normalization by 18S
ribosome RNA, and presented as the comparison with the cultured cells transfected with the control siRNA oligos. The open bar represents the cells
transfected with control siRNA, and the values have been normalized to 1. The fold changes of the target genes were presented when compared with
those transfected with control siRNA. The black bar represents cells transfected with siRNA targeting TP53, while the blue bar represents cells
transfected with siRNA targeting NF-kB subunit, RelA/p65. * refers to statistical significance (t test, P,0.05).
doi:10.1371/journal.pone.0073656.g005
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[27], indicating that IL8 up-regulation requires a complex
modulation among the three TFs. Apart from IL8, the co-
regulation between NF-kB and AP1, CEBPB or STAT3 for genes
IL1B, ICAM1, IL6, PTGS2, and SAA1 in the TF regulatory
networks (Figure 2B) is consistent with previous observation in
HNSCC or other cancer cells [49,50,51,52,53,54]. By promoter
analysis, the co-binding motifs of NF-kB with AP1, STAT3 and
EGR1 has been identified on clustered genes over-expressed in the
HNSCC cell lines [15]. In addition, we observed that a larger
number of predicted NF-kB and p53 target genes in the two
inferred gene regulatory programs are consistent with the known
ones (Figure 2B), by comparison with the overall prediction of
their target genes. This result provides evidence for the accuracy of
inferred regulatory programs in the HNSCC cell lines. Through
experimental examination on the targets of NF-kB and p53
involved in these networks, we confirm that their expression was
significantly altered in the both wt and mt p53 tumor cell lines
after the knockdown of RelA and TP53 (Figure 5). Thus, we
experimentally validated a group of newly predicted NF-kB or p53
target genes, which support the prediction power of this new
system biology approach to integrating multiple platforms and
data involved in the transcriptional and regulatory interactions
among NF-kB, p53 and the other TFs.
Our results demonstrate that the target genes in the transcrip-
tional regulatory programs mediate a variety of functional
processes, consistent with previous experimental reports on NF-
kB genes that regulate apoptosis, adhesion, angiogenesis, inflam-
matory and immune responses, proliferation, and migration in
HNSCC cells [15,16,22,55].The co-target genes of NF-kB and
p53, such as CAKN1A, IGFBP3, IL1A, IL1B, IL1RN, IL6, IL8,
ITGA3, ITGA5, LAM3A, LAM3B, PTGS2, SFN, are presented
significantly in enriched pathways in the Table 2 have been
examined experimentally in this study (Figures 5, 6), and from
previous reports [16,56,57,58]. Distinct signal pathways identified
are more specific to different phenotypes in the tumor cells related
with different p53 status (Table 2). For example, genes significantly
enriched in TGFb pathway are repressed in the tumor cells with
the wt p53-deficient status (Table S3B). This finding is consistent
with the negative regulatory function of TGFb in HNSCC cells,
observed by Lu, et al. [59]. Our work establishes a strong link with
regulatory programs of NF-kB and p53, and their related
pathways or functional processes, in agreement with many
conclusions previously drawn from the biologic experiments.
Discovery of TF and miRNA interactive modules can advance
our understanding of complex transcriptional regulatory architec-
tures in cancer cells. We chose mir21 and mir34ac in light of their
involvement in p53 or NF-kB signaling pathway for reconstructing
transcriptional and post-transcriptional gene regulatory networks.
The over-expression of oncogenic mir21 was constantly observed
in 15 of 16 microarray studies based on diverse HNSCC samples
whereas aberrant expression of tumor suppresser mir34 family was
identified in 6 of these studies (data not shown). It is reasoned that
the two miRNAs are likely involved in transcriptional modulation
of NF-kB or p53 during HNSCC development. We constructed
two gene networks regulated by the four factors in the cell lines of
HNSCC (Figure 3). To assess our result, we first identified a large
fraction of network genes which are known NF-kB target genes.
These genes mediate immune and inflammatory responses (CSF2,
IL1A, IL1B, IL1RN, IL1R2, IL6, and IL8), apoptosis (CDKN1A and
IGFBP3), and adhesion (ITGA5, LAMA3, LAMB3 and ICAM1),
validated in HNSCC cell lines (Figure 5, and [16]). Moreover,
some of known p53 binding targets such as CDKN1A, IGFBP3,
PERP, PTGS2, S100A2, SERPINB5, SERPINE1, SFN, and TP63
are also components of the networks. Second, we have experi-
mentally confirmed a number of predicted targets of p53 in the
networks by silencing of TP53 and testing binding activities of p53
on their promoters in the tumor cells (Figures 5, 6). p53 binding
activity assay on the gene promoters provides functional evidence
for the regulatory networks (Figure 6). This newly developed assay
mimics traditional gel shift assay (EMSA), using DNA oligos with
biotin labeling instead radioisotope (Active Motif). The advantage
of this assay over commonly used ChIP assay is using more defined
binding oligo sequence that contains only 40–60 nucleotides.
However, in ChIP assay, the DNA sequence involved in the TF
Figure 6. Binding activity of p53 on the promoters of selected genes. Nuclear extract from UM-SCC 1 cells were isolated, and the binding
activity was examined on the biotin labeled oligos containing promoter sequences with p53 binding sites. The binding activity of nuclear extract of
MCF-7 cells with a biotinylated oligonucleotide containing a known p53 binding site in the CDKN1A gene promoter (‘‘MCF-7 p21 oligo’’) was served
as a positive control. Specificity of binding in the UM-SCC cells was also tested using cold competition (unbiotinylated) oligonucleotides which
contained the wild-type p53 consensus binding sequence (‘‘wt competition’’) or mutant DNA sequence of p53 binding site (‘‘mt competition’’).The
mean and standard deviation of each binding was calculated from triplicate, and the presented data are from one representative of repeated
experiments. *refers to statistical significance when p53 binding activity was competed by the mt oligo, to confirm the binding specificity (t test,
P,0.05).
doi:10.1371/journal.pone.0073656.g006
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and antibody complex is usually 100–500 bp long, where many
potential binding activities may be involved with other binding
motifs [60]. Third, it is noticeable that more than a half of genes in
the TF regulatory programs (Figure 2B) overlap with the networks
of TF-miRNA (Figure 3), demonstrating a coordinated interaction
of mir21 and mir34ac with multiple TFs contributing to transcrip-
tional regulation of genes. Several known or likely target genes of
mir21 or mir34ac were identified in the networks, providing
evidence for the miRNA involvement. Two genes SERPINB5 and
TP63 are known targets of mir21 and p53, where TP63 is also a
transcriptional target of NF-kB [61]. Thus, TP63 is likely a key gene
interconnected by NF-kB, p53 and mir21. On the other hand, as
one of the p53 family members, the TAp63 isoform is able to exert
biological functions similar to those of p53 and contributes to
oncogenesis and tumor-suppressor activity [62]. We have shown
that some p53 genes in the networks are also known to be regulated
by p63, such as CDKN1A, IGFBP3, PERP, S100A2, SERPINB5, and
SFN. Another example gene JAG1 is a known binding target of
mir21, mir34a and p63, supporting the potential of p63 interacting
with TFs and miRNAs in gene regulation of HNSCC. Recently, we
demonstrated that DNp63 interacts with NF-kB subunit cRel or
RelA to modulate gene programs mediating apoptosis, cell growth
arrest, inflammation, epidermal hyperplasia and the malignant
phenotypes of HNSCC cells [20,36].
Furthermore, we found that many genes in the TF-miRNA
networks are related to biological processes contributing to the
progression of HNSCC. Several common target genes in the
networks were down-regulated in both wt and mt tumor cells
(Figure 3, Table S4), such as ITGA5 and S100A2 (adhesion and
migration), SERPINE1 (angiogenesis), CDKN1A (growth arrest),
and PLAU and SERPINE5 (proteolysis). These cellular processes
possibly favor HNSCC metastasis [39]. The two miRNAs may
interact with p53 or NF-kB to modulate their target expression so
that repressing progression of HNSCC. By contrast, the over-
expressed genes in the networks may trigger tumorigenesis of
HNSCC by altering gene expression associated with inflammatory,
proliferation, apoptosis and other processes (Figure 3, Table S4),
such as IL6, IGFBP3, ELF3, and PTGES in the both subgroups of
tumor cells. The miRNAs and TFs likely mediate metastatic
processes through the increased expression of their target genes,
such as IL8, ICAM1 and TGFBI in the wt p53-decifient cells, or
SPP1 and PTK2 in the mt p53 cells (Figure 3, Table S4). To validate
the results in the cell lines, we constructed two regulatory networks
by analyzing datasets of metastatic and non-metastatic HNSCC
tissues (Figure 4). Several important genes associated with tumor
metastatic program, such as IL6, IL8, MMP1, PLAU, SERPINB5,
SERPINE1, SPP1, TGFBI, TNC and TP63 were consistently
confirmed in the both tumor cell lines and tissues.
miRNAs are implicated in tumor progression, as metastasis
activators or suppressors [63,64]. mir21, as a master regulator of
the metastatic processes was found to stimulate cell invasion by
targeting tumor suppressors TPM1, PDCD4 and SERPINB5 in
breast cancer [65] or colon cancer [66]. As the mediator of tumor
suppression by p53, mir34 family may contribute to the inhibition
of invasion or metastasis in various cancer types [67]. mir34ac
could serve as a metastasis suppressor to regulate breast cancer
migration and invasion through targeting oncogene Fos-related
antigen 1 [68]. In human malignant melanoma, an over-
expression of mir34ac suppresses invasive growth of tumor cells
with wild-type p53 gene [69]. In the networks of HNSCC
metastatic tissues (Figure 4), we identified several representative
miRNA targets BCL2, MMP9, SERPINE5, TPM1, and TP63,
consistent with the previous experimental results derived from
miRNA target databases TarBase and mir2disease. The anti-
apoptotic BCL2, a known binding target of mir21 and mir34ac, is
co-regulated by NF-kB and p53 in oral metastatic tissues
(Figure 4B), suggesting a model for the interaction between TFs
and miRNAs in facilitating tumor progression and metastasis.
Taken together, our analyses provide a view of cross-regulatory
relationships among NF-kB, p53 and the miRNAs in different
malignant phenotypes. To our knowledge, this is the first
investigation of TF-miRNA regulatory interactions by modeling
diverse data sources in HNSCC. Within experimental validation
of predicted miRNA targets, it should help understanding of
transcriptional and post-transcriptional regulatory mechanisms
responsible for heterogeneity of HNSCC.
Conclusions
In summary, our analysis indicates that two master TFs, NF-
kB and p53, have a wide impact on distinct or shared biological
functions in HNSCC cells, through a coordinated interaction to
regulate gene expression programs. A certain number of the
identified genes have previously been examined as known NF-kB
or p53 targets, or validated by siRNA knock down of the two TF
genes and p53 binding activity assay. Furthermore, we have
found that NF-kB, p53 and two miRNAs, mir21 and mir34ac,
may constitute concerted regulatory modules and play an
important role in modulating downstream gene networks
contributing to metastatic processes of HNSCC. Through the
integrated analyses, our studies provide a framework for
experimental analysis of TF-miRNA regulatory modules, and
insights into the complex regulatory mechanisms underlying
squamous cell carcinoma. The identified gene programs are
highly associated with cancer-related pathways and functions,
suggesting that the newly developed method is suitable to
inferring the gene regulatory networks in these cancer data.
Application of the new methodology in HNSCC has showed that
it can be utilized as a useful approach to study on other biological
complex systems.
Supporting Information
Figure S1 A map of transcriptional regulatory network
in HNSCC cell lines. In the figure, every node (grey one)
represents a target gene of at least one of TFs RelA/p65, NFkB1/
p50, cRel, p53, AP1, CEBPB, EGR1, SP1 and STAT3 (pink
nodes). A, the wt p53-deficient cells. B, the mt p53 cells.
(PDF)
Table S1 List of TF target genes predicted by regulatory
component analysis model-based method. The genes in
red and green represent differentially over- and under-expressed
with fold change $2.0 in HNSCC cell lines of the wt or mt p53.
(PDF)
Table S2 Overlapping of target genes between NF-kB or
p53 and other TFs in HNSCC cell lines.
(PDF)
Table S3 Significant enrichment of biological functions
among common target genes between NF-kB and p53 in
HNSCC cell lines. Joint target genes of NF-kB and p53 were
annotated to, A. GO biological processes by using DAVID tool
with P,0.001, FDR ,2%. B, Canonical signaling pathways by
using Ingenuity Pathway Analysis tools (P,0.05). Genes in red
and green indicate the over- and under-expressed genes in
HNSCC cell lines above at least 2 fold changes, respectively.
(PDF)
Regulatory Networks in Head and Neck Cancer
PLOS ONE | www.plosone.org 13 September 2013 | Volume 8 | Issue 9 | e73656
Table S4 Target genes of mir21 and mir34ac and their
overlapping with NF-kB and p53 targets in HNSCC cell
lines. Based on miRNA databases TarBase and mir2disease,
‘‘target validated’’ refers to target genes of mir21 or mir34ac tested
by reporter assay, and ‘‘target likely’’ refers to genes of mir21 or
mir34ac tested by other methods (such as microarray, qRT-PCR,
Western blot, and proteomics). The number in the parenthesis
refers to number of computational methods ($3) for the miRNA
target gene prediction based on miRecords. The genes in red and
green represent differentially over- and under-expressed at least
fold change 2.0 in the wt and mt p53 cells.
(PDF)
Table S5 Overlapped target genes of NF-kB, p53, mir21
and mir34ac in HNSCC tissues. (Legends see Table S4).
(PDF)
Text S1 Binding data of TFs and miRNAs.
(PDF)
Author Contributions
Conceived and designed the experiments: MZ ZC BY. Performed the
experiments: XY MJ. Analyzed the data: BY HL JS DG XY MJ.
Contributed reagents/materials/analysis tools: XY ZC CVW HL. Wrote
the paper: BY HL MZ ZC CVW SZ. Algorithm development: HL SZ
MZ.
References
1. Chen G, Jensen ST, Stoeckert CJ Jr. (2007) Clustering of genes into regulons
using integrated modeling-COGRIM. Genome Biol 8: R4.
2. Tang B, Hsu HK, Hsu PY, Bonneville R, Chen SS, et al. (2012) Hierarchical
modularity in ERalpha transcriptional network is associated with distinct
functions and implicates clinical outcomes. Sci Rep 2: 875.
3. Li H, Sun Y, Zhan M (2007) The discovery of transcriptional modules by a two-
stage matrix decomposition approach. Bioinformatics 23: 473–479.
4. Geeven G, van Kesteren R, Smit A, de Gunst M (2012) Identification of context-
specific gene regulatory networks with GEMULA – gene expression modeling
using LAsso. Bioinformatics 28: 214–221.
5. Georgiev P, Theis F, Cichocki A, Bakardjian H (2006) Sparse component
analysis: a new tool for data mining. Biocomputing: Kluwer Academic
Publishers.
6. Dueck D, Morris QD, Frey BJ (2005) Multi-way clustering of microarray data
using probabilistic sparse matrix factorization. Bioinformatics 21 Suppl 1: i144–
i151.
7. Pournara I, Wernisch L (2008) Using temporal correlation in factor analysis for
reconstructing transcription factor activities. EURASIP J Bioinform Syst Biol:
172840.
8. Liao JC, Boscolo R, Yang YL, Tran LM, Sabatti C, et al. (2003) Network
component analysis: reconstruction of regulatory signals in biological systems.
Proc Natl Acad Sci U S A 100: 15522–15527.
9. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:
2893–2917.
10. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB (2011) NF-
kappaB addiction and its role in cancer: ‘one size does not fit all’. Oncogene 30:
1615–1630.
11. Schneider G, Kramer OH (2011) NFkappaB/p53 crosstalk-a promising new
therapeutic target. Biochim Biophys Acta 1815: 90–103.
12. Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell
132: 344–362.
13. Menendez D, Inga A, Resnick MA (2009) The expanding universe of p53
targets. Nat Rev Cancer 9: 724–737.
14. Sidransky D (2002) Emerging molecular markers of cancer. Nat Rev Cancer 2:
210–219.
15. Yan B, Yang X, Lee TL, Friedman J, Tang J, et al. (2007) Genome-wide
identification of novel expression signatures reveal distinct patterns and
prevalence of binding motifs for p53, nuclear factor-kappaB and other signal
transcription factors in head and neck squamous cell carcinoma. Genome Biol 8:
R78.
16. Yan B, Chen G, Saigal K, Yang X, Jensen ST, et al. (2008) Systems biology-
defined NF-kappaB regulons, interacting signal pathways and networks are
implicated in the malignant phenotype of head and neck cancer cell lines
differing in p53 status. Genome Biol 9: R53.
17. Karin M (2006) NF-kappaB and cancer: mechanisms and targets. Mol Carcinog
45: 355–361.
18. Baud V, Karin M (2009) Is NF-kappaB a good target for cancer therapy? Hopes
and pitfalls. Nat Rev Drug Discov 8: 33–40.
19. Chen Z, Yan B, Van Waes C (2008) The Role of the NF-kappaB Transcriptome
and Proteome as Biomarkers in Human Head and Neck Squamous Cell
Carcinomas. Biomark Med 2: 409–426.
20. Lu H, Yang X, Duggal P, Allen CT, Yan B, et al. (2011) TNF-alpha promotes c-
REL/DeltaNp63alpha interaction and TAp73 dissociation from key genes that
mediate growth arrest and apoptosis in head and neck cancer. Cancer Res 71:
6867–6877.
21. Brown MS, Diallo OT, Hu M, Ehsanian R, Yang X, et al. (2010) CK2
modulation of NF-kappaB, TP53, and the malignant phenotype in head and
neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm
nanocapsules. Clin Cancer Res 16: 2295–2307.
22. Ondrey FG, Dong G, Sunwoo J, Chen Z, Wolf JS, et al. (1999) Constitutive
activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human
head and neck squamous cell carcinoma cell lines that express pro-inflammatory
and pro-angiogenic cytokines. Mol Carcinog 26: 119–129.
23. Worden B, Yang XP, Lee TL, Bagain L, Yeh NT, et al. (2005) Hepatocyte
growth factor/scatter factor differentially regulates expression of proangiogenic
factors through Egr-1 in head and neck squamous cell carcinoma. Cancer Res
65: 7071–7080.
24. Noda C, Murata T, Kanda T, Yoshiyama H, Sugimoto A, et al. (2011)
Identification and characterization of CCAAT enhancer-binding protein (C/
EBP) as a transcriptional activator for Epstein-Barr virus oncogene latent
membrane protein 1. J Biol Chem 286: 42524–42533.
25. Shin JA, Kim JJ, Choi ES, Shim JH, Ryu MH, et al. (2012) In vitro apoptotic
effects of methanol extracts of Dianthus chinensis and Acalypha australis L.
targeting specificity protein 1 in human oral cancer cells. Head Neck.
26. Lee TL, Yeh J, Friedman J, Yan B, Yang X, et al. (2008) A signal network
involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/
BCL-XL expression and promotes cell survival of head and neck squamous cell
carcinomas. Int J Cancer 122: 1987–1998.
27. Freund A, Jolivel V, Durand S, Kersual N, Chalbos D, et al. (2004) Mechanisms
underlying differential expression of interleukin-8 in breast cancer cells.
Oncogene 23: 6105–6114.
28. Pensa S, Watson CJ, Poli V (2009) Stat3 and the inflammation/acute phase
response in involution and breast cancer. J Mammary Gland Biol Neoplasia 14:
121–129.
29. Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, et al. (2002)
Induction of tissue factor expression in human endothelial cells by CD40 ligand
is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol
Chem 277: 25032–25039.
30. Takahra T, Smart DE, Oakley F, Mann DA (2004) Induction of myofibroblast
MMP-9 transcription in three-dimensional collagen I gel cultures: regulation by
NF-kappaB, AP-1 and Sp1. Int J Biochem Cell Biol 36: 353–363.
31. Papagiannakopoulos T, Shapiro A, Kosik KS (2008) MicroRNA-21 targets a
network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 68:
8164–8172.
32. Boldin MP, Baltimore D (2012) MicroRNAs, new effectors and regulators of NF-
kappaB. Immunol Rev 246: 205–220.
33. Hermeking H (2009) The miR-34 family in cancer and apoptosis. Cell Death
Differ.
34. Lee TL, Yang XP, Yan B, Friedman J, Duggal P, et al. (2007) A novel nuclear
factor-kappaB gene signature is differentially expressed in head and neck
squamous cell carcinomas in association with TP53 status. Clin Cancer Res 13:
5680–5691.
35. Hoyer PO (2004) Non-negative matrix factorization with sparseness constraints.
J Mach Learn Res 5: 1457–1469.
36. Yang X, Lu H, Yan B, Romano RA, Bian Y, et al. (2011) DeltaNp63 versatilely
regulates a Broad NF-kappaB gene program and promotes squamous epithelial
proliferation, migration, and inflammation. Cancer Res 71: 3688–3700.
37. Xiao F, Zuo Z, Cai G, Kang S, Gao X, et al. (2009) miRecords: an integrated
resource for microRNA-target interactions. Nucleic Acids Res 37: D105–110.
38. Nguyen DX, Bos PD, Massague J (2009) Metastasis: from dissemination to
organ-specific colonization. Nat Rev Cancer 9: 274–284.
39. Chen ZG (2007) Exploration of metastasis-related proteins as biomarkers and
therapeutic targets in the treatment of head and neck cancer. Curr Cancer Drug
Targets 7: 613–622.
40. Cromer A, Carles A, Millon R, Ganguli G, Chalmel F, et al. (2004)
Identification of genes associated with tumorigenesis and metastatic potential
of hypopharyngeal cancer by microarray analysis. Oncogene 23: 2484–2498.
41. O’Donnell RK, Kupferman M, Wei SJ, Singhal S, Weber R, et al. (2005) Gene
expression signature predicts lymphatic metastasis in squamous cell carcinoma of
the oral cavity. Oncogene 24: 1244–1251.
42. Friedman J, Nottingham L, Duggal P, Pernas FG, Yan B, et al. (2007) Deficient
TP53 Expression, Function, and Cisplatin Sensitivity Are Restored by
Quinacrine in Head and Neck Cancer. Clin Cancer Res 13: 6568–6578.
43. Ikeda A, Sun X, Li Y, Zhang Y, Eckner R, et al. (2000) p300/CBP-dependent
and -independent transcriptional interference between NF-kappaB RelA and
p53. Biochem Biophys Res Commun 272: 375–379.
Regulatory Networks in Head and Neck Cancer
PLOS ONE | www.plosone.org 14 September 2013 | Volume 8 | Issue 9 | e73656
44. Dell’Orso S, Fontemaggi G, Stambolsky P, Goeman F, Voellenkle C, et al.
(2011) ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene
promoters. OMICS 15: 305–312.
45. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. (1993)
WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817–825.
46. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, et al. (2006) A global map of p53
transcription-factor binding sites in the human genome. Cell 124: 207–219.
47. Botcheva K, McCorkle SR, McCombie WR, Dunn JJ, Anderson CW (2011)
Distinct p53 genomic binding patterns in normal and cancer-derived human
cells. Cell Cycle 10: 4237–4249.
48. Wang J, Ouyang W, Li J, Wei L, Ma Q, et al. (2005) Loss of tumor suppressor
p53 decreases PTEN expression and enhances signaling pathways leading to
activation of activator protein 1 and nuclear factor kappaB induced by UV
radiation. Cancer Res 65: 6601–6611.
49. Wang T, Zou J, Cunningham C, Secombes CJ (2002) Cloning and functional
characterisation of the interleukin-1 beta 1 promoter of rainbow trout
(Oncorhynchus mykiss). Biochim Biophys Acta 1575: 108–116.
50. Catron KM, Brickwood JR, Shang C, Li Y, Shannon MF, et al. (1998)
Cooperative binding and synergistic activation by RelA and C/EBPbeta on the
intercellular adhesion molecule-1 promoter. Cell Growth Differ 9: 949–959.
51. Tamura M, Sebastian S, Yang S, Gurates B, Fang Z, et al. (2002) Interleukin-
1beta elevates cyclooxygenase-2 protein level and enzyme activity via increasing
its mRNA stability in human endometrial stromal cells: an effect mediated by
extracellularly regulated kinases 1 and 2. J Clin Endocrinol Metab 87: 3263–
3273.
52. Li X, Liao WS (1992) Cooperative effects of C/EBP-like and NF kappa B-like
binding sites on rat serum amyloid A1 gene expression in liver cells. Nucleic
Acids Res 20: 4765–4772.
53. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, et al. (2000)
Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell
carcinogenesis in vivo. Proc Natl Acad Sci U S A 97: 4227–4232.
54. Hong SH, Ondrey FG, Avis IM, Chen Z, Loukinova E, et al. (2000)
Cyclooxygenase regulates human oropharyngeal carcinomas via the proin-
flammatory cytokine IL-6: a general role for inflammation? Faseb J 14: 1499–
1507.
55. Duffey DC, Chen Z, Dong G, Ondrey FG, Wolf JS, et al. (1999) Expression of a
dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in
human head and neck squamous cell carcinoma inhibits survival, proinflamma-
tory cytokine expression, and tumor growth in vivo. Cancer Res 59: 3468–3474.
56. Rasmussen MK, Iversen L, Johansen C, Finnemann J, Olsen LS, et al. (2008)
IL-8 and p53 are inversely regulated through JNK, p38 and NF-kappaB p65 in
HepG2 cells during an inflammatory response. Inflamm Res 57: 329–339.
57. Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC, et al. (2001) Hepatocyte growth
factor/scatter factor-induced activation of MEK and PI3K signal pathways
contributes to expression of proangiogenic cytokines interleukin-8 and vascular
endothelial growth factor in head and neck squamous cell carcinoma. Cancer
Res 61: 5911–5918.
58. Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, et al. (2002) Effects of
pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK
signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF
expression in human head and neck squamous cell carcinoma lines. Int J Cancer
99: 538–548.
59. Lu SL, Herrington H, Reh D, Weber S, Bornstein S, et al. (2006) Loss of
transforming growth factor-beta type II receptor promotes metastatic head-and-
neck squamous cell carcinoma. Genes Dev 20: 1331–1342.
60. Furey TS (2012) ChIP-seq and beyond: new and improved methodologies to
detect and characterize protein-DNA interactions. Nat Rev Genet 13: 840–852.
61. Wu J, Bergholz J, Lu J, Sonenshein GE, Xiao ZX (2010) TAp63 is a
transcriptional target of NF-kappaB. J Cell Biochem 109: 702–710.
62. Candi E, Dinsdale D, Rufini A, Salomoni P, Knight RA, et al. (2007) TAp63
and DeltaNp63 in cancer and epidermal development. Cell Cycle 6: 274–285.
63. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA (2009) MicroRNAs – the
micro steering wheel of tumour metastases. Nat Rev Cancer 9: 293–302.
64. Nohata N, Hanazawa T, Kinoshita T, Okamoto Y, Seki N (2013) MicroRNAs
function as tumor suppressors or oncogenes: aberrant expression of microRNAs
in head and neck squamous cell carcinoma. Auris Nasus Larynx 40: 143–149.
65. Zhu S, Wu H, Wu F, Nie D, Sheng S, et al. (2008) MicroRNA-21 targets tumor
suppressor genes in invasion and metastasis. Cell Res 18: 350–359.
66. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, et al. (2008)
MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor
Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer.
Oncogene 27: 2128–2136.
67. Bader AG (2012) miR-34 – a microRNA replacement therapy is headed to the
clinic. Front Genet 3: 120.
68. Yang S, Li Y, Gao J, Zhang T, Li S, et al. (2012) MicroRNA-34 suppresses
breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene.
69. Yamazaki H, Chijiwa T, Inoue Y, Abe Y, Suemizu H, et al. (2012)
Overexpression of the miR-34 family suppresses invasive growth of malignant
melanoma with the wild-type p53 gene. Exp Ther Med 3: 793–796.
Regulatory Networks in Head and Neck Cancer
PLOS ONE | www.plosone.org 15 September 2013 | Volume 8 | Issue 9 | e73656
